🔥 TRENDING Maharashtra CM Fadnavis Unveils A.R. R... CJP’s Dipke, Das, Ranka to Host Youth... India to Clean Heritage Sites Starting... Five-Century Palace Falls into Neglect... Samaleswari SC Set to Clash with Nagal... MCPCR Holds Consultative Meeting on Ch...
20 Nov 2026•
ગુજરાતી मराठी ਪੰਜਾਬੀ বাংলা
Lupin Receives Single USFDA Observation at Goa Facility
📷 Image: Wikimedia Commons / Abidlone
Business

Lupin Receives Single USFDA Observation at Goa Facility

✍️ Sahi 🗓 25 Oct 2026, 12:18 PM 👁 79
Share: 💬 WhatsApp 📘 Facebook 𝕏 Post

Indian drugmaker Lupin has been issued one observation by the U.S. Food and Drug Administration concerning its manufacturing site in Goa, according to a report by Sahi. The observation highlights a compliance issue that the company must address.

Lupin Limited, a leading Indian pharmaceutical company, received a single observation from the U.S. Food and Drug Administration (USFDA) regarding its manufacturing facility in Goa.

The observation, issued by the USFDA's Office of Regulatory Affairs, points to a specific compliance concern that the company must rectify to maintain its Good Manufacturing Practice (GMP) certification.

Lupin has stated it will cooperate fully with the regulator and will implement corrective actions promptly.

The company has previously faced regulatory scrutiny in other jurisdictions, but this is the first USFDA observation for its Goa plant.
📲Get App